Cardiomyopathy

(redirected from Ischemic cardiomyopathy)
Also found in: Dictionary, Thesaurus, Medical, Acronyms.

cardiomyopathy

[¦kärd·ē·ō‚mī′äp·ə·thē]
(medicine)

Cardiomyopathy

 

(myocardosis), a term often applied to a broad group of heart diseases; specifically, noninflammatory lesions of the heart muscle (myocardium) resulting from a disturbance in myocardial metabolism. Among the causes of cardiomyopathy are nutritional disorders (alimentary dystrophy and avitaminosis, for example); protein metabolism disorders in hepatic or renal insufficiency and podagra; disturbances of carbohydrate metabolism (diabetes mellitus) and electrolyte metabolism; and endocrine disorders such as those associated with thyrotoxicosis and with hypoxia in impairment of coronary circulation, anemia, and mountain sickness. Myocardosis may also be caused by overstraining the myocardium and by exogenous poisons, such as carbon monoxide and alcohol.

In many cases the patient has no specific symptoms in the early stages; however, there may be shortness of breath and disagreeable sensations in the heart. Cardiomyopathy is manifested by dull, distant heart sounds, electrocardiographic changes, systolic murmur, extrasystole, and, more rarely, other types of arrhythmia. Severe cardiomyopathy weakens the heart contractions and may cause cardiac insufficiency. The changes associated with cardiomyopathy are usually reversible and disappear with the elimination of the underlying disease.

The cure includes treatment of the underlying disease and administration of agents that improve metabolic processes in the myocardium.

REFERENCE

Kedrov, A. A. Bolezni myshtsy serdtsa. Leningrad, 1963.

N. R. PALEEV

References in periodicals archive ?
Comparison of 40 mg versus 10 mg atorvastatin on the level of serum prostacyclin and platelet activation in patients with Ischemic Cardiomyopathy.
Coverage of the Ischemic Cardiomyopathy pipeline on the basis of route of administration and molecule type.
The next step is to expand the investigation of percutaneous, intramyocardial ixmyelocel-T treatment in a larger sample of heart failure patients with ischemic cardiomyopathy.
Juventas also presented an update from STOP-HF, a Phase 2 study of 93 patients with symptomatic ischemic cardiomyopathy in a double-blind, randomized, placebo-controlled trial to evaluate safety and efficacy of JVS-100.
OTCQB: BHRT) announced that that the first successful intracoronary implantation of autologous adipose-derived stem cell (ADSC) was performed in a 70-year-old male with ischemic cardiomyopathy.
The diagnostic has been evaluated prospectively in patients with ischemic cardiomyopathy, nonischemic dilated cardiomyopathy, or mixed cardiomyopathy.
OTCQB: BHRT) announced that the first successful intracoronary implantation of autologous adipose-derived stem cell (ADSC) was performed in a 70-year-old male with ischemic cardiomyopathy.
November 18, 2013 -- Scientists here conducted a study to examine the safety of transcndocardial stem cell injection (TESI) with autologous mesenchymal stem cells and bone marrow mononuclear cells in patients with ischemic cardiomyopathy.
The company added that it recently applied to the FDA to begin trials using adipose derived stem cells in patients with chronic ischemic cardiomyopathy.
For primary prevention in asymptomatic patients with ischemic cardiomyopathy and an ejection fraction of less than 30%, implantable cardioverter defibrillators (ICDs) are the best choice, as shown in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).